कैनाग्लिफ्लोज़िन के इंटरैक्शन

Hypoglycemia Chloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life-threatening in patients treated with or without antidiabetic medications (see PRECAUTIONS , Drug Interactions ). (क्लोरोक्वीन लेबल, चेतावनियां)

This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. (ग्लिपिज़ाइड और मेटफॉर्मिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Oral hypoglycemics Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. (फ्लुकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Antidiabetic agents Hypoglycemia including fatal outcomes have been reported. (सिप्रोफ्लॉक्सासिन लेबल, दवाओं के इंटरैक्शन)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (हाइड्रॉक्सीक्लोरोक्वीन लेबल, चेतावनियां और सावधानियां)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Antidiabetic Drugs Repaglinide Saxagliptin Monitor for adverse reactions. (इट्राकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (एटाज़ानाविर लेबल, चेतावनियां और सावधानियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Monitor blood glucose in patients with diabetes and assess if antidiabetic agent dose modifications are required. (एबिराटेरोन लेबल, चेतावनियां और सावधानियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Glyburide: In a trial of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose-lowering effect of glyburide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects. (एसिट्रेटिन लेबल, दवाओं के इंटरैक्शन)

Oral Hypoglycemics Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. (एस्पिरिन और डाइपिरिडामोल लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (ऑक्ट्रियोटाइड लेबल, चेतावनियां और सावधानियां)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

A reduction in dose of oral hypoglycemic medication (e.g., sulfonylureas) or insulin may be required in some patients [see Clinical Studies (14) ] . (ऑर्लिस्टैट लेबल, चेतावनियां और सावधानियां)

Fluoroquinolones have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (ओफ्लॉक्सासिन लेबल, चेतावनियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Insulin and oral hypoglycemics action may be enhanced. (कार्वेडिलोल लेबल, दवाओं के इंटरैक्शन)

Antidiabetics repaglinide, saxagliptin Antihelmintics and Antiprotozoals praziquantel Antimigraine Drugs ergot alkaloids, such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine) eletriptan Ergot alkaloids: The potential increase in plasma concentrations of ergot alkaloids when coadministered with ketoconazole tablets… (कीटोकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Closely monitor for adverse reactions of CYP2C9 substrates where minimal concentration changes may lead to serious adverse reactions when used concomitantly with XELODA (e.g., anticoagulants, antidiabetic drugs). (कैपेसिटाबिन लेबल, दवाओं के इंटरैक्शन)

Oral Hypoglycemic Agents/Insulin: The concomitant use of clarithromycin tablets and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia. (क्लैरिथ्रोमाइसिन लेबल, चेतावनियां और सावधानियां)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (टिमोलोल लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (ट्रायमसिनोलोन लेबल, दवाओं के इंटरैक्शन)

(See PRECAUTIONS . ) Antidiabetic Agents Concomitant use of ACE inhibitors and antidiabetic medicines (insulin or oral hypoglycemic agents) may cause an increased blood glucose lowering effect with greater risk of hypoglycemia. (ट्रैंडोलाप्रिल लेबल, दवाओं के इंटरैक्शन)

Hypoglycemia in Diabetic Patients Some MAOIs have contributed to hypoglycemic episodes in diabetic patients receiving insulin or other blood-glucose-lowering agents. (ट्रैनिलसाइप्रोमिन लेबल, चेतावनियां और सावधानियां)

Initiation or dose adjustments of insulin or oral hypoglycemic agents may be required. (डारुनाविर लेबल, चेतावनियां और सावधानियां)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (डारुनाविर और कोबिसिस्टैट लेबल, चेतावनियां और सावधानियां)

Digoxin Clinical Impact: Canagliflozin increases digoxin exposure [see Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Caution should be exercised when used with antidiabetic drugs. (डैनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (डोरज़ोलामाइड और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (नाडोलोल लेबल, चेतावनियां)

Use of Antidiabetic Medications: Weight loss may cause hypoglycemia. (नाल्ट्रेक्सोन और ब्यूप्रोपियॉन लेबल, चेतावनियां और सावधानियां)

Examples: Rifampin, phenytoin, phenobarbital, ritonavir Insulin or Insulin Secretagogues Clinical Impact: The risk of hypoglycemia is increased when INVOKANA is used concomitantly with insulin secretagogues (e.g., sulfonylurea) or insulin. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (पिंडोलोल लेबल, चेतावनियां)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Monitor patients for the development of edema when co-administering LYRICA CR and thiazolidinedione antidiabetic agents. (प्रीगैबलिन लेबल, चेतावनियां और सावधानियां)

Antidiabetic agents: May increase blood glucose concentrations. (प्रेडनिसोन लेबल, दवाओं के इंटरैक्शन)

Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (प्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

• A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (फेंटरमिन लेबल, चेतावनियां और सावधानियां)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Examples: Rifampin, phenytoin, phenobarbital, ritonavir Insulin or Insulin Secretagogues Clinical Impact: The risk of hypoglycemia is increased when INVOKANA is used concomitantly with insulin secretagogues (e.g., sulfonylurea) or insulin. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Examples: Rifampin, phenytoin, phenobarbital, ritonavir Insulin or Insulin Secretagogues Clinical Impact: The risk of hypoglycemia is increased when INVOKANA is used concomitantly with insulin secretagogues (e.g., sulfonylurea) or insulin. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Examples: Rifampin, phenytoin, phenobarbital, ritonavir Insulin or Insulin Secretagogues Clinical Impact: The risk of hypoglycemia is increased when INVOKANA is used concomitantly with insulin secretagogues (e.g., sulfonylurea) or insulin. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (फोसएम्प्रेनाविर लेबल, चेतावनियां और सावधानियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

As is true with many other types of medication when taken concurrently by patients with diabetes, insulin and/or oral hypoglycemic, dosage may need to be adjusted when therapy with PROZAC is instituted or discontinued. (फ्लुओक्सेटिन लेबल, चेतावनियां और सावधानियां)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (फ्लुड्रोकॉर्टिसोन लेबल, दवाओं के इंटरैक्शन)

However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (बिसोप्रोलोल लेबल, चेतावनियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules exceeds maximum recommended daily dosage. (ब्यूटाल्बिटल, एस्पिरिन और कैफीन लेबल, दवाओं के इंटरैक्शन)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (ब्यूटाल्बिटल, एस्पिरिन, कैफीन और कोडीन लेबल, दवाओं के इंटरैक्शन)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (ब्रिमोनिडिन और टिमोलोल लेबल, चेतावनियां और सावधानियां)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Antidiabetics : Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (मिथाइलप्रेडनिसोलोन लेबल, दवाओं के इंटरैक्शन)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Antidiabetic agents Carefully monitor blood glucose. (मॉक्सीफ्लॉक्सासिन लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Examples: Rifampin, phenytoin, phenobarbital, ritonavir Insulin or Insulin Secretagogues Clinical Impact: The risk of hypoglycemia is increased when INVOKANA is used concomitantly with insulin secretagogues (e.g., sulfonylurea) or insulin. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Examples: Rifampin, phenytoin, phenobarbital, ritonavir Insulin or Insulin Secretagogues Clinical Impact: The risk of hypoglycemia is increased when INVOKANA is used concomitantly with insulin secretagogues (e.g., sulfonylurea) or insulin. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

• Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA ( 5.5 ). (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Lithium Clinical Impact: Concomitant use of an SGLT2 inhibitor with lithium may decrease serum lithium concentrations. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (लिनेज़ोलिड लेबल, चेतावनियां और सावधानियां)

• Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. (लियोथायरोनिन लेबल, चेतावनियां और सावधानियां)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (लिसिनोप्रिल लेबल, दवाओं के इंटरैक्शन)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Worsening of Diabetic Control : May worsen glycemic control and result in increased antidiabetic agent or insulin requirements. (लेवोथायरोक्सिन लेबल, चेतावनियां और सावधानियां)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (लेवोथायरोक्सिन और लियोथायरोनिन लेबल, दवाओं के इंटरैक्शन)

Blood Glucose Disturbances Fluoroquinolones, including Levofloxacin in 5% Dextrose Injection, have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (लेवोफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (लैनरियोटाइड लेबल, चेतावनियां और सावधानियां)

Examples: Rifampin, phenytoin, phenobarbital, ritonavir Insulin or Insulin Secretagogues Clinical Impact: The risk of hypoglycemia is increased when INVOKANA is used concomitantly with insulin secretagogues (e.g., sulfonylurea) or insulin. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Sulfonylurea Oral Hypoglycemics (CYP2C9 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Frequent monitoring of blood glucose and for signs and symptoms of hypoglycemia. (वोरिकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Precipitating conditions for diabetic ketoacidosis or other ketoacidosis include under-insulinization due to insulin dose reduction or missed insulin doses, acute febrile illness, reduced caloric intake, ketogenic diet, surgery, volume depletion, and alcohol abuse. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Like other sulfonamide-containing drugs, sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics. (सल्फामेथॉक्साज़ोल और ट्राइमेथोप्रिम लेबल, दवाओं के इंटरैक्शन)

Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (साल्सालेट लेबल, दवाओं के इंटरैक्शन)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (सुनिटिनिब लेबल, चेतावनियां और सावधानियां)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (सोटालोल लेबल, दवाओं के इंटरैक्शन)

The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (सोमाट्रोपिन लेबल, चेतावनियां और सावधानियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

Antidiabetic Agents Clinical Impact: Corticosteroids in supraphysiologic doses may increase blood glucose concentrations. (हाइड्रोकॉर्टिसोन लेबल, दवाओं के इंटरैक्शन)

Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (कैनाग्लिफ्लोज़िन लेबल, चेतावनियां और सावधानियां)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (क्लोज़ापिन लेबल, चेतावनियां और सावधानियां)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (ज़िप्रासिडोन लेबल, चेतावनियां और सावधानियां)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (टेल्मिसार्टन और एम्लोडिपिन लेबल, दवाओं के इंटरैक्शन)

Hypoglycemic Agents: In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. (टोल्मेटिन लेबल, दवाओं के इंटरैक्शन)

Antidiabetic drug requirements (i.e., insulin) may be altered. (डाइएथिलप्रोपियॉन लेबल, दवाओं के इंटरैक्शन)

Glucose Lowering Drugs Pioglitazone: Co-administration of pioglitazone for 7 days with 30 mg nifedipine ER administered orally q.d. for 4 days to male and female volunteers resulted in least square mean (90% CI) values for unchanged nifedipine of 0.83 (0.73-0.95) for C max and 0.88 (0.80-0.96) for AUC relative to nifedipine monotherapy. (निफेडिपिन लेबल, सावधानियां)

Insulin and Oral Hypoglycemic Medications Requirements may be altered. (फेनडाइमेट्राज़िन लेबल, दवाओं के इंटरैक्शन)

Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin, use of anorectic drugs, excessive use of alcohol, use of benzodiazepines, sedatives/hypnotics, or opiates. (ब्यूप्रोपियॉन लेबल, चेतावनियां और सावधानियां)

Although the systemic absorption of miconazole following ORAVIG administration is minimal and plasma concentrations of miconazole are substantially lower than when given intravenously, the potential for interaction with drugs metabolized through CYP2C9 and CYP3A4 such as oral hypoglycemics, phenytoin, or ergot alkaloids cannot be ruled out. (माइकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Moexipril hydrochloride has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H 2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. (मोएक्सिप्रिल लेबल, दवाओं के इंटरैक्शन)

Oral Hypoglycemic Agents In pharmacokinetic studies of lovastatin in hypercholesterolemic non-insulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide (see CLINICAL PHARMACOLOGY , Clinical Studies in Adults ). (लोवास्टेटिन लेबल, दवाओं के इंटरैक्शन)

Potentiation of the action of sulfonylurea hypoglycemic agents, thiazide diuretics and uricosuric agents may also be noted. (सल्फाडायज़िन लेबल, दवाओं के इंटरैक्शन)

Oral hypoglycemic agents Although sulindac and its sulfide metabolite are highly bound to protein, studies in which sulindac was given at a dose of 400 mg daily, have shown no clinically significant interaction with oral hypoglycemic agents. (सुलिंडैक लेबल, दवाओं के इंटरैक्शन)